Pitcairn’s Ginkgo Bioworks DNA Stock Holding History

Pitcairn’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-262	Closed	-$17.7K	–	607
2022 Q4	$17.7K	Buy	+262	New	+$24.1K	﹤0.01%	582

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Pitcairn's DNA Position: Q1 2023 in Review

Pitcairn sold out of Ginkgo Bioworks (DNA) in Q1 2023, closing a stake of 262 shares — an estimated $17.7K sold.

Pitcairn first reported a position in DNA in Q4 2022 and held it in 1 quarter. The position peaked at $17.7K in Q4 2022. 313 funds tracked by Wall St. Rank hold DNA as of Q1 2023.

Pitcairn reported no remaining Ginkgo Bioworks position as of Q1 2023 after selling out during the quarter.
Pitcairn sold 262 Ginkgo Bioworks shares in Q1 2023, an estimated $17.7K.
Pitcairn first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 1 quarter.
Pitcairn's Ginkgo Bioworks position peaked at $17.7K in Q4 2022.
313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2023.

Based on Pitcairn's 13F filing for Q1 2023, filed 5 May 2023.